Al-Razi Medicalشركة الرازي الطبية
- Price
- 30.96 SAR
- Fair value
- 10.92 SAR
- Discount to fair value
- −183%
- Mkt cap
- 47.06M
- P/E
- 57.4×
- P/B
- 2.00×
- EV
- 58.67M
- ROE
- 3.5%
- Net margin
- 1.1%
Current price30.96SAR
Fair value (est., median)10.92SAR
UndervaluedFair valueOvervalued
+183.5% above fair valueWould need to fall ~64.7% to reach fair value.
Median ofDCF 78.56Graham 14Residual Income 2.38Earnings Power 7.85
Health Check
30.1
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
—
Risks
- Trades 183.5% above estimated fair value.
- Low fair-value confidence — methods disagree or data is thin.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for details
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 |
|---|---|---|---|---|
| Revenue | 52.39M | 61.33M | 61.35M | 74.38M |
| Net Income | 2.01M | 686.0K | 175.9K | 819.5K |
| Net Margin | 3.8% | 1.1% | 0.3% | 1.1% |
| Operating Cash Flow | 2.05M | 5.78M | 4.96M | 5.82M |
| OCF Margin | 3.9% | 9.4% | 8.1% | 7.8% |
| Capital Expenditure | — | 5.07M | 3.87M | 1.98M |
| Free Cash Flow | 2.05M | 709.8K | 1.09M | 3.84M |
| FCF Margin | 3.9% | 1.2% | 1.8% | 5.2% |
| FCF Conversion | 101.9% | 103.5% | 619.7% | 469.0% |
| EPS (Diluted) | 1.33/sh | 0.45/sh | 0.12/sh | 0.54/sh |
| Dividend / Share | — | 1.59/sh | — | — |
Dividend return (if you buy today)
This company doesn’t currently pay a dividend, so there’s no income return to project. The fair-value gauge above covers the price side.
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | — | — |
| 2024 | — | — | — | — | — | — |
| 2023 | — | — | — | — | 1.59 | 2.4% |
| 2022 | — | — | — | — | — | — |
Corporate actions
DCash Dividend
0.39 /sh2023-09-05
Valuation breakdown
Fair value = median of the applicable methods (DCF، Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Values the company from the future cash it's expected to generate. · Tap to adjust assumptions
78.56
Dividend Discount Model
Excluded — company pays no dividend
N/A
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
14.00
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
2.38
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
7.85
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)10.92
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 6.76%
- CAPM cost of equity
- 7.18%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in Al-Razi Medical regularly?
Starting year
- Invested
- 1K/yr · 4K total(2023 → today · 4 yrs)
- your value today is
- 2.7K SAR
- Total return
- -31.9%(+0.2% Dividends · -32.1% Capital gain)
- Annualised (IRR)
- -19.5%
Invested4KSAR
Dividends8SAR
Capital gain-1.3KSAR
InvestedCapital gainDividendstap a bar for figures
Major shareholders
As of 2026-06-16Disclosed holders at or above the 5% reporting threshold.
يوسف بن عبدالله بن يوسف العريني
57.37%
Total disclosed57.37%
The Saudi Exchange publishes only holders at or above 5%; smaller stakes are not disclosed.
Community Notes0
No notes yet. Be the first to share a thesis.